Drug Trial Radar · NCT06751485
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
430
Planned (sponsor's estimate)
Start
Jan 15, 2025
Primary completion
Dec 30, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.
Conditions
- Ovarian Cancer
- Primary Peritoneal
- Fallopian Tube Cancers
Interventions
JSKN003Drug
Experimental drug
DoxorubicinDrug
Active Comparator
PaclitaxelDrug
Active Comparator
TopotecanDrug
Active Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC) as per RECIST 1.1Time frame: Up to approximately 22 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.